Meeting
2018 Genitourinary Cancers Symposium
Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.
Authors
Glenn Bubley
Beth Israel Deaconess Medical Center, Boston, MA
Glenn Bubley , Irving D. Kaplan , Lillian Werner , Rupal Satish Bhatt , Mary Ellen Taplin , Kathleen Margaret Mahoney , Paul Nguyen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT0208988
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 58)
DOI
10.1200/JCO.2018.36.6_suppl.58
Abstract #
58
Poster Bd #
C22
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
First Author: Bertrand F. Tombal
Poster
2018 Genitourinary Cancers Symposium
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
First Author: Fernando C. Maluf
Poster
2014 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.
First Author: Bertrand Tombal
Poster
2024 ASCO Genitourinary Cancers Symposium
ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
First Author: Andrew Leonard Laccetti